News | October 10, 2025
AstraZeneca to increase investment in Virginia manufacturing facility to $4.5 billion
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
The platform is being introduced to expand access to treatments for people living with chronic conditions
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
The medicine was well tolerated, with no unexpected safety issue
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Subscribe To Our Newsletter & Stay Updated
